Cargando…
Rituximab in Refractory Myositis and Acute Neuropathy Secondary to Checkpoint Inhibitor Therapy
Checkpoint inhibitor immunotherapies have been one of the latest advances through the last decade in the treatment of various cancers. As their use is increasing so is the knowledge of their complications which can affect various organ systems including the central and peripheral nervous systems. Ma...
Autores principales: | Jain, Varun, Remley, William, Bunag, Cyra, Elfasi, Aisha, Chuquilin, Miguel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9206120/ https://www.ncbi.nlm.nih.gov/pubmed/35733495 http://dx.doi.org/10.7759/cureus.25129 |
Ejemplares similares
-
Biologic predictors of clinical improvement in rituximab-treated refractory myositis
por: Reed, Ann M., et al.
Publicado: (2015) -
Nonepileptic, Stereotypical, and Intermittent Symptoms After Subdural Hematoma Evacuation
por: Jain, Varun, et al.
Publicado: (2021) -
Refractory Orbital Myositis in Systemic Lupus Erythematosus A Role for Rituximab
por: Rodrigues Morais, Joana, et al.
Publicado: (2021) -
Efficacy and Safety of Rituximab in Chinese Children With Refractory Anti-NMDAR Encephalitis
por: Dou, Xiangjun, et al.
Publicado: (2020) -
Posterior Fossa Progressive Multifocal Leukoencephalopathy Secondary to Rituximab
por: Guduru, Mounika, et al.
Publicado: (2020)